MAPT and Alzheimer disease: This concept arises from evidence that brain insulin resistance, a hallmark of type 2 diabetes mellitus, drives AD pathology by impairing amyloid-β clearance, promoting tau hyperphosphorylation, and exacerbating neuroinflammation [53,54].